Details of the Metabolic Reaction (MR)

General Information of This Metabolic Reaction (MR) (ID: MR001498)
Formula
DDC
SVG example
Decarboxylation
Reactant Levodopa Product Dopamine
Reactant Info Product Info
Metabolic Enzyme DOPA decarboxylase (DDC) DME Info
Metabolic Type Oxidation - Decarboxylation
Other MR(s) Related to The Reactant of This MR
Other MR(s) That Metabolize The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR001500 Levodopa 3-O-Methyldopa Conjugation - Methylation Levodopa [1], [2], [3], [4]
MR001499 Levodopa Levodopa Methylated metabolite Conjugation - Methylation Levodopa [5]
Other MR(s) Related to The Product of This MR
Other MR(s) That Produce The Product of This MR
MR ID Reactant Product MR Type Related Drug REF
MR008912 DEC-TA-870 Dopamine Unclear - Unclear Docarpamine [6]
Other MR(s) That Metabolize The Produtc of This MR
MR ID Reactant Product MR Type Related Drug REF
MR001486 Dopamine 3,4-Dihydroxyphenylacetaldehyde (DOPAL) Oxidation - Oxidative Deamination Levodopa [5]
MR001485 Dopamine 3-Methoxytyramine Conjugation - O-Methylation Levodopa [5]
MR001488 Dopamine Dopamine-3-O-glucuronide Oxidation - N-Dealkylation Levodopa [5]
MR001490 Dopamine Dopamine-3-O-sulfate Conjugation - Sulfation Levodopa [5]
MR001489 Dopamine Dopamine-4-O-glucuronide Oxidation - N-Dealkylation Levodopa [5]
MR001491 Dopamine Dopamine-4-O-sulfate Conjugation - Sulfation Levodopa [5]
MR001487 Dopamine Norepinephrine Oxidation - Hydroxylation Levodopa [5]
MR008915 Dopamine 3,4-dihydroxyphenylacetic acid Unclear - Unclear Docarpamine [6]
MR008913 Dopamine 3-methoxytyramine Unclear - Unclear Docarpamine [6]
⏷ Show the Full List of MR
References
1 Motor complications, levodopa metabolism and progression of Parkinson's disease Expert Opin Drug Metab Toxicol. 2011 Jul;7(7):847-55. doi: 10.1517/17425255.2011.575779.
2 Impact of the catechol-O-methyltransferase Val158Met polymorphism on the pharmacokinetics of L-dopa and its metabolite 3-O-methyldopa in combination with entacapone. J Neural Transm (Vienna). 2021 Jan;128(1):27-36. doi: 10.1007/s00702-020-02267-y.
3 Mass spectrometry imaging identifies abnormally elevated brain l-DOPA levels and extrastriatal monoaminergic dysregulation in l-DOPA-induced dyskinesia. Sci Adv. 2021 Jan 6;7(2):eabe5948. doi: 10.1126/sciadv.abe5948. Print 2021 Jan.
4 Pharmacokinetics of Levodopa and 3-O-Methyldopa in Parkinsonian Patients Treated with Levodopa and Ropinirole and in Patients with Motor Complications. Pharmaceutics. 2021 Sep 3;13(9):1395. doi: 10.3390/pharmaceutics13091395.
5 DrugBank(Pharmacology-Metabolism)Levodopa
6 Metabolism of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl)dopamine (TA-870) and dopamine after oral administration to rats and dogs

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.